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Abstract
Background: Charcot-Marie-Tooth2b (CMT2b) is an axonal form of a human neurodegenerative disease that
preferentially affects sensory neurons. CMT2b is dominantly inherited and is characterized by unusually early onset,
presenting in the second or third decade of life. Five missense mutations in the gene encoding Rab7 GTPase have
been identified as causative in human CMT2b disease. Although several studies have modeled CMT2b disease in
cultured neurons and in Drosophila, the mechanisms by which defective Rab7 leads to disease remain poorly
understood.
Results: We used zebrafish to investigate the effects of CMT2b-associated Rab7 mutations in a vertebrate model.
We generated transgenic animals expressing the CMT2b-associated mutant forms of Rab7 in sensory neurons,
and show that these Rab7 variants cause neurodevelopmental defects, including defects in sensory axon
growth, branching and pathfinding at early developmental stages. We also find reduced axon growth and
branching in neurons expressing a constitutively active form of Rab7, suggesting these defects may be
caused by Rab7 gain-of-function. Further, we use high-speed, high-resolution imaging of endosome transport
in vivo and find that CMT2b-associated Rab7 variants cause reduced vesicle speeds, suggesting altered
transport may underlie axon development defects.
Conclusions: Our data provide new insight into how disease-associated alterations in Rab7 protein disrupt
cellular function in vertebrate sensory neurons. Moreover, our findings suggest that defects in axon
development may be a previously unrecognized component of CMT2b disease.
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Background
Charcot-Marie-Tooth2b (CMT2b) is an axonal form of
peripheral neuropathy characterized by loss of sensation
in multiple somatosensory modalities, motor abnormal-
ities, and a very early disease onset in the second or
third decade of life [1, 2]. CMT2b is an autosomal
dominant disease, caused by five missense mutations in
the Rab7 gene (L129F, K157N, N161I, N161T, V162M)
[3–6]. Rab7 is a small GTPase associated with late endo-
somal membrane compartments that has known roles
in conversion of early endosomes to late endosomes,
biogenesis of lysosomes, and maturation of autopha-
gosomes [7, 8]. In addition, Rab7 has been shown to
regulate retrograde trafficking, signaling and lysosomal
degradation of neurotrophin receptors [7–11]. Like other
GTPases, Rab7 cycles between a membrane-bound, active,
GTP-bound form, and a cytosolic, inactive, GDP-bound
form. CMT2b-associated amino acid substitutions occur in
the proximity of the GTP-binding pocket and hydrolysis
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domains, and affect GDP and GTP exchange, increasing
both Rab7 activation and hydrolysis-dependent inactiva-
tion, resulting in a form of Rab7 that is prone to remain in
the active, GTP-bound form [12–14]. This finding, to-
gether with the dominant inheritance of the human dis-
ease, has led to the hypothesis that the disease is caused
by overactivity of Rab7. However, several lines of evidence
suggest the mutations do not cause simple gain of Rab7
function, but rather more complex alterations in function.
Rab7 proteins containing the CMT2b-associated amino
acid substitutions (hereafter referred to as CMT2b Rab7
mutants) show significantly lower affinity for both GDP
and GTP [13], suggesting they could have reduced func-
tion. Indeed, when CMT2b Rab7 mutants are expressed
in Drosophila photoreceptors, they are inefficiently re-
cruited to endosomes, consistent with reduced function
[15]. In contrast, although the CMT2b Rab7 mutants do
cycle between membrane-associated and cytosolic states,
they exhibit decreased ability to disassociate from the
membrane, which leads to increased activity and aug-
ments interaction with several Rab7 effectors [14]. More-
over, the mutations do not interfere with the ability of
Rab7 to bind its effector RILP and in some cases CMT2b
Rab7 mutants are able to rescue Rab7 loss of function
[12, 13, 15], which suggests retention of some wild-
type function.
Several studies have investigated mechanisms by which
the CMT2b mutations lead to disease by expressing
CMT2b Rab7 mutants in cell lines or cultured neurons.
CMT2b Rab7 mutants disrupted NGF signaling, NGF-
induced neurite outgrowth, and trafficking of TrkA recep-
tors in PC12 cells and DRG neurons [11, 16], suggesting
that loss of neurotrophic support may contribute to
CMT2B disease. In addition, expression of CMT2b Rab7
mutants in established DRG cultures caused neurite loss,
indicating an axon degeneration effect [11]. Expres-
sion of CMT2b Rab7 mutants caused decreased neur-
ite outgrowth in neuroblastoma cells, which could be
reversed by treatment with valproic acid, an activator
of extracellular signal-regulated kinase (ERK) and c-Jun
terminal kinase (JNK) signaling pathways, both of the
mitogen activated protein kinase (MAPK) superfamily
[17, 18], suggesting this signaling pathway plays a role
in the disease mechanism. Two recent studies expressed
CMT2b Rab7 mutants in Drosophila to model the disease
[15, 19]. One of these studies found that overexpression of
CMT2b Rab7 mutants had no detectable effects on motor
neuron or photoreceptor function, and suggested the
CMT2b disease effects are due to partial loss of Rab7
function [15]. The second study showed that expression of
the L129F CMT2b variant in Drosophila sensory neurons
causes reduced pain and temperature sensation and is
consistent with dominant effects of the mutant variants
[19]. However, to date no vertebrate CMT2b models have
been developed for in vivo analysis of the long sensory
axons analogous to those affected in human disease.
Analyses of the transport dynamics of vesicles contain-
ing the CMT2b Rab7 mutants have also given varied
results. CMT2b Rab7 mutants caused increased trans-
port rates of vesicles in DRG neurons, an effect that
was mimicked by a constitutively active Rab7, Q67L
(CA-Rab7) [11]. Expression of CMT2b Rab7 mutants
in Drosophila sensory neurons did not alter endosome
speed but did result in fewer stationary vesicles [19].
Overall, the diverse and sometimes contradictory find-
ings from studies in different systems and cell types
indicate that the CMT2b Rab7 mutants have complex
effects on the cell biology of neurons, and highlight
the need for additional models for analysis of disease
mechanism.
We developed a vertebrate model of CMT2b by ex-
pressing CMT2b Rab7 mutants in zebrafish spinal sensory
neurons in vivo. The zebrafish model provides a distinct
advantage that cellular processes can be analyzed and
imaged in vertebrate sensory axons within the intact,
living animal. We demonstrate that CMT2b Rab7 mutants
cause defects in axon growth, branching and pathfinding
in developing sensory neurons. Some of these defects are
phenocopied by expression of CA-Rab7, but not by dom-
inant negative Rab7, T22N (DN-Rab7), consistent with a
partial gain of function effect of the CMT2b mutants. We
also use high speed imaging of vesicle dynamics in devel-
oping neurons in vivo and find that CMT2b Rab7 mutants
cause reduced vesicle transport speeds, suggesting altered
transport may underlie axon development defects. Our
data suggest that defects in axon development may be a
previously unrecognized component of CMT2b disease.
Results
Peripheral sensory neuron outgrowth and branching are
reduced in CMT2b Rab7 mutant expressing neurons
To investigate the effects of CMT2b mutations in a
vertebrate model, we used zebrafish Rohon-Beard (RB)
spinal sensory neurons. Zebrafish Rab7 shares 97.6 %
amino acid identity with the human Rab7 protein, in-
cluding the amino acid residues that are affected in
the human disease, L129F, K157N, N161T, and V162M
[3–5] (Fig. 1a), which makes the zebrafish an excellent
vertebrate organism in which to model this disease. Using
single-site mutagenesis, we generated these CMT2b dis-
ease mutations in the zebrafish rab7 cDNA and expressed
these constructs in RB neurons under control of cis-
regulatory elements from the neurogenin1 gene [20]
(-3.1ngn:GFP-Rab7-cmt2b). In humans CMT2b is auto-
somal dominant—the presence of only one copy of the
mutated gene causes disease. Thus, we modeled the
disease by expressing the CMT2b Rab7 mutants in a back-
ground containing wildtype Rab7.
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We first expressed the constructs transiently by inject-
ing DNA into 1-cell stage embryos, which results in
mosaic labeling of individual sensory neurons, and ana-
lyzed the effects on neuronal morphology at 23 hpf,
when RB axon arbors are developing. RB neurons have
stereotyped morphology; they extend two central axons
that ascend and descend ipsilaterally in the spinal cord,
and one peripheral axon that extends to the skin where
it branches extensively. We first analyzed outgrowth and
branching of the peripheral RB axon. Neurons express-
ing wildtype Rab7 (n = 31 cells in 19 embryos) showed
normal morphology (Fig. 1b), with most extending a
peripheral axon by this stage. Only 13 % of these
neurons failed to extend a peripheral axon, which is the
same proportion we previously found for wildtype RB
neurons expressing only GFP (4 of 31 cells expressing
wildtype Rab7, and 3 of 23 cells expressing GFP alone,
failed to extend a peripheral axon, p = 0.99, Chi-Square
test) [21]. This result suggests that overexpression of
wildtype Rab7 in the neuron does not induce axon
growth defects. In contrast, expression of CMT2b Rab7
mutants caused defects in outgrowth of the peripheral
RB axons (Fig. 1c-f ). Overall, 20–50 % of RB neurons
expressing CMT2b Rab7 mutants failed to extend a
peripheral axon. The effects of the four different mutant
variants were variable, and only K157N and V162M
showed statistically significant effects on peripheral axon
outgrowth (Fig. 1f ). In addition, the peripheral axons
that did form showed decreased branching. We quantified
axon branching by counting the number of peripheral
Fig. 1 Decreased peripheral axon branching in sensory neurons expressing CMT2b Rab7 mutants. a Comparison of zebrafish and human Rab7
protein sequence in the region of CMT2b mutations. Differences in amino acid sequence indicated by asterisks. Amino acid residues associated
with CMT2b are bolded. b-e Confocal images of individual RB neurons expressing wildtype GFP-Rab7 (b) or CMT2b GFP-Rab7 mutants (c) in
embryos with all RB neurons labeled with HNK-1 antibody (red). Anterior to the left. b wildtype Rab7 expressing cell shows wide arborization of
peripheral axons (yellow arrow). c Lack of peripheral axon outgrowth in Rab7 L129F expressing cell. d, e Reduced peripheral branching (yellow
arrow) in Rab7 K157N (D) and Rab7 N161T (E) expressing cells. Asterisk =missing central axon. f Quantification of number of neurons extending
peripheral axons. Cont = wildtype Rab7: n = 31 cells in 19 embryos; Rab7 L129F: n = 33 cells in 24 embryos, p = 0.08; Rab7 K157N: n = 10 cells in
10 embryos, *p = 0.03; Rab7 N161T: n = 15 cells in 14 embryos, p = 0.6; Rab7 V162M: n = 23 cells in 18 embryos, *p = 0.05. Fisher’s exact tests.
g Quantification of peripheral branch endings in CMT2b-associated Rab7 mutations shows a significant decrease in branching. Wildtype Rab7:
n = 20 cells in 15 embryos; Rab7 L129F: n = 21 cells in 18 embryos; Rab7 K157N: n = 11 cells in 7 embryos; Rab7 N161T: n = 12 cells in 10 embryos;
Rab7 V162M: n = 16 cells in 14 embryos. *p = 0.03, **p < 0.01; Unpaired two-tailed t-test. Scale bar = 40 μm
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axon endings and found a significant reduction in the
number of branches in neurons expressing any of the four
CMT2b Rab7 mutants (Fig. 1g). These results suggest that
CMT2b Rab7 mutants influence both the ability of the
peripheral axon to form and its capacity to extend second-
ary branches.
Constitutively Active (CA) Rab7 inhibits sensory
peripheral axon outgrowth and branching
To ask whether the effect on RB peripheral axon growth
and branching is caused by overactive Rab7 or partial
loss of Rab7 function, we analyzed the effects of express-
ing the previously characterized DN-Rab7 (T22N) or
CA-Rab7 (Q67L) [22]. We expressed these constructs
under control of the -3.1ngn1 sensory neuron promoter.
Like the CMT2b Rab7 mutants, expression of CA-Rab7
in wildtype embryos caused defects in RB peripheral axon
outgrowth and branching. Significantly fewer RB neurons
extended a peripheral axon compared to neurons express-
ing wildtype Rab7 (Fig. 2a-b, e). Further, the peripheral
axons that did grow out had fewer branches (Fig. 2c, f-g).
In contrast, DN-Rab7 expression had no significant effect
on RB axon development (Fig. 2d, e-g). The similarity in
phenotype caused by the CMT2b Rab7 mutants and the
CA-Rab7 suggest that CMT2b mutant effects on sensory
axon development are caused at least in part by Rab7 gain
of function.
CMT2b-associated Rab7 mutants cause central axon
guidance defects
We analyzed the RB central axon projections and found
that expression of CMT2b Rab7 mutants also caused
defects in central axon growth and guidance (Fig. 3). All
neurons expressing wildtype Rab7 showed normal cen-
tral axon growth and trajectories (Fig. 3a), as did all
neurons expressing GFP alone analyzed previously [21].
In contrast, a significant percentage of neurons express-
ing L129F and K157N mutants were lacking a central
axon (Fig. 3b, d). Further, we found that expression of
the L129F Rab7 mutant caused errors in central axon
guidance (Fig. 3c, e). In neurons expressing L129F Rab7,
central axons left the dorsal longitudinal fascicle and
either extended along the ventral spinal cord, or crossed
the midline to join the contralateral fascicle. Misguided
central axons were seen in sensory neurons expressing
any of the four CMT2b Rab7 mutants, but only at sig-
nificant numbers for L129F. Interestingly, we did not
detect central axon defects in neurons expressing either
CA-Rab7 or DN-Rab7 (n = 30 cells expressing CA-Rab7,
n = 14 cells expressing DN-Rab7), suggesting this effect
is a result of alteration in Rab7 function specifically caused
by the disease-related mutation.
Sensory neurons expressing stable CMT2b Rab7 mutant
transgenes exhibit central and peripheral axon defects
Transient mosaic expression of plasmid DNA constructs
results in variable, and often very high protein expres-
sion levels in individual cells. To drive expression at con-
sistent, moderate levels in all RB neurons and thereby
more closely model the human disease, we generated
stable transgenic lines expressing either GFP-Rab7, GFP-
Rab7L129F or GFP-Rab7K157N under control of the
-3.1ngn1 promoter, using the Tol2 transposase system,
which typically results in integration of single copies of
the transgene [23, 24]. We raised F1 carriers of the trans-
gene and examined F2 offspring for expression of the
constructs. We found that most or all RB neurons express
the GFP-Rab7s and that GFP fluorescence levels appeared
lower than in embryos transiently expressing plasmid
DNA. We analyzed the whole RB population by labeling
Tg(-3.1ngn1:GFP-Rab7-CMT2b) embryos with HNK1
antibody (Fig. 4a-c). We found that similar to cells transi-
ently expressing CMT2b Rab7 mutants, RB neurons in
transgenic 23 hpf embryos showed reduced peripheral
axon branching compared to those expressing wildtype
Rab7. To quantify branching in the population of RB cells,
we counted the number of peripheral axon branches
that cross the point of the horizontal myoseptum,
and found a significant reduction in the embryos ex-
pressing the CMT2b Rab7 mutants (Fig. 4g). To analyze
individual cell morphology in these embryos, we labeled
cells mosaically by injecting -3.1ngn1:TagRFP-CAAX DNA
into 1-cell stage transgenic embryos that express the
CMT2b Rab7 mutants in all RB neurons. We quantified
the number of peripheral axon endings in individually
labeled RB neurons, and found a significant reduction in
branching of neurons in both the L129F and K157N Rab7
mutant transgenics (Fig. 4h).
To ask whether the reduced branching is due to a
failure to initiate peripheral axon branches versus de-
creased stability or maintenance of branches, we analyzed
earlier developmental stages. We again mosaically labeled
neurons by injecting -3.1ngn1:TagRFP-CAAX DNA into
transgenic embryos that express the CMT2b Rab7 mu-
tants in all RB neurons. We analyzed embryos between
18–21 hpf, stages when peripheral axons are initiating
growth. We categorized individually labeled cells into 3
groups: no peripheral axon (example shown in Fig. 4i), a
peripheral growth cone just beginning initiation (e.g.
Fig. 4j), or a peripheral axon extended out of the spinal
cord (e.g. Fig. 4k). We found no significant difference
in peripheral axon initiation between wildtype, CMT2b
L129F or CMT2b K157N embryos at either 18–19 hpf or
20–21 hpf (Fig. 4l, m). We further measured the number
of peripheral branch endings in the cells that had ex-
tended peripheral axons, and found no decrease in initial
branch formation in the CMT2b Rab7 mutant expressing
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embryos, and in fact a statistically significant increase in
the CMT2b K157N embryos (Fig. 4n). These data suggest
the earliest stages of outgrowth and branching can occur
normally in CMT2b Rab7 mutant expressing neurons,
perhaps even to an accelerated degree, but these neurons
fail to sustain further growth and branching.
In addition to peripheral axon branching defects, the
L129F and K157M transgenic embryos also exhibited
central axon guidance defects (Fig. 5), although only in
significant numbers for L129F (Fig. 5d). Guidance de-
fects included axons leaving the central axon fascicle
(Fig. 5b), and central axons crossing the midline to join
the contralateral central axon fascicle (Fig. 5c). Interest-
ingly, some cells had two central axons that correctly
entered the ipsilateral fascicle, with an extra axon that
crossed the midline to join the contralateral fascicle of
central axons. No guidance defects were found in wildtype
Rab7 expressing neurons. Together, our data indicate
that in addition to known neurodegenerative effects,
the CMT2b Rab7 mutants also cause defects in sensory
axon guidance and branch formation during development
of the sensory circuitry.
CMT2b Rab7 transgenics do not show premature RB cell
death
RB neurons normally undergo programmed cell death
during larval stages, and their stage of death is regulated
in part by neurotrophin signaling [25]. To ask whether
the CMT2b Rab7 mutants influence RB cell survival, we
analyzed RB cell number at 3 days post fertilization
(dpf). We labeled RB cell bodies in 3 dpf embryos with
anti-HuC/D, and counted the number of cell bodies in 5
segments beginning at the end of the yolk extension
(Fig. 6a, b). We found no reduction in cell number in
the CMT2b Rab7 transgenics, and instead found a slight
increase in the CMT2b L129F embryos (Fig. 6c). These
data suggest that the earlier axon growth defects do not
directly inhibit cell survival at later stages.
CMT2b Rab7 mutants disrupt endosome dynamics in vivo
Previous studies of CMT2b Rab7 mutant effects on vesicle
transport in cultured cells or in Drosophila neurons have
given diverse results [11, 19]. To explore the effects of
CMT2b Rab7 mutants on endosome transport in verte-
brate embryos, we performed high speed, high resolution
in vivo imaging of vesicle movement using swept field
confocal microscopy [26], as we have done previously
[21]. We transiently expressed either wildtype GFP-Rab7
or the CMT2b Rab7 mutant constructs by DNA injection
at the 1-cell stage, and imaged vesicles in neurons at 24
hpf (Fig. 7). To quantify axonal transport rates of labeled
endosomes, we generated kymographs and performed
several quantifications of endosome dynamics. Because
the average speed of vesicle movement is not representa-
tive of dynamic, saltatory movement, we first calculated
the speed of the fastest run during a 400 s imaging period.
We observed a marked decrease in speed of K157N Rab7-
containing vesicles (Fig. 7a-d, e). A previous study found
that CMT2b L129F Rab7 mutant vesicles pause less often
in Drosophila sensory neurons [19]. We also quantified
the number of stationary versus moving vesicles, and
found fewer stationary CMT2b Rab7 mutant containing
vesicles, although this result was only significant for the
N161T and V162M Rab7 variants (Fig. 7a-d, f ). Finally, to
ask if the CMT2b mutants affect vesicle directionality, we
analyzed the direction of vesicle movement. We found no
significant difference in the directionality of CMT2b
mutant Rab7 vesicles (73 % of wildtype Rab7 vesicles
moved retrogradely, n = 98 vesicles in 4 embryos; 83 % of
L129F Rab7 vesicles moved retrogradely, n = 35 vesicles in
3 embryos, p = 0.4; 66 % of N161T Rab7 vesicles moved
retrogradely, n = 76 vesicles in 7 embryos, p = 0.3; 66 % of
V162M Rab7 vesicles moved retrogradely, n = 38 vesicles
in 4 embryos, p = 0.4, Fischer’s exact test).
Expression of CMT2b Rab7 mutants does not significantly
enlarge vesicles in RB sensory neurons
Rab7 is involved in late endosome maturation and forma-
tion of lysosomes and autophagosomes [7, 8]. A previous
study of cultured cells suggested that CMT2b Rab7
mutants may interfere with Rab7 function in vesicular
trafficking and maturation by forming large, vacuolar-like
structures, although this effect was seen in PC12 cells, but
not in DRG cells [11]. To test the possibility that endo-
some size is affected by the CMT2b Rab7 mutants in
neurons in vivo, we measured the volume of endosomes
(See figure on previous page.)
Fig 2 Peripheral axon outgrowth and branching defects in CA-Rab7 expressing neurons. a-c Confocal projections of embryos with all RBs labeled
with HNK-1 antibody (red) and individual RBs labeled with indicated Rab7 forms (green). Drawings at right highlight morphology of one neuron
in green. a Individual RB neuron labeled with GFP-Rab7 showing central axons extending anteriorly and posteriorly from the cell body, and peripheral
axon branching in the skin. b Lack of peripheral axon outgrowth in GFP-Rab7 Q67L (CA) expressing cell. c Reduced peripheral branching in GFP-Rab7
Q67L (CA) expressing cell. d Normal central outgrowth and peripheral branching in GFP-Rab7 T22N (DN) mutant expressing RB cell. e Expression of
CA-Rab7, but not DN-Rab7, mutant construct increases percentage of RB neurons that do not extend a peripheral axon. n = 31 cells in Rab7 control, 30
cells in CA-Rab7, and 14 cells in DN-Rab7, **p = 0.006, Chi-Square test. f Number of peripheral axons that cross horizontal myoseptum (H.M.) is reduced
in CA-Rab7 expressing cells. CA-Rab7: n = 9 cells; wildtype Rab7 control: n = 12 cells. **p = 0.009, paired t-test. g Number of peripheral axon endings in
individually labeled neurons **p = 0.005, Unpaired two tailed t-test. Wildtype Rab7: 31 cells in 19 embryos; Rab7 Q67L: 30 cells in 15 embryos; Rab7
T22N: 14 cells in 9 embryos. All views anterior to the left. Scale bar = 40 μm
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in central and peripheral axons and found no significant
difference in the vesicular volume between wildtype Rab7
and the CMT2b Rab7 mutants (3.8 ± 0.5 μm3 in wildtype
Rab7, n = 85 endosomes; 4.1 ± 0.5 μm3 in Rab7 L129F,
p = 0.1, unpaired, two tailed, t-test, n = 187 endosomes;
7.0 ± 1.1 μm3 in Rab7 K157N, p = 0.06, unpaired, two-
tailed t-test, n = 84 endosomes; 4.7 ± 0.9 μm3 in Rab7
V162M, p = 0.07, unpaired two-tailed t-test). These results
are consistent with a previous finding that CMT2b Rab7
variants did not interfere with endosomal maturation
when expressed in Drosophila [15].
Discussion
In this study we provide the first vertebrate model to
investigate the mechanisms by which CMT2b disease
associated mutations affect the cell biology of sensory
neurons in vivo. We find that expression of CMT2b
Rab7 mutants causes developmental defects in vertebrate
sensory neurons, including reduced axon outgrowth, re-
duced axon branching, as well as axon guidance errors.
Furthermore, we use live, high-speed, high-resolution
imaging to show that CMT2b Rab7 mutants alter endo-
some transport during axon development in vivo. Overall,
these results suggest there may be a developmental
component of CMT2b, and that sensory circuits may not
form properly in CMT2b disease.
CMT is an unusual form of a neurodegenerative neur-
opathy, in that it has an early manifestation during the
second or third decade of life. Prior studies have suggested
that neurodegeneration of long sensory axons are the pri-
mary pathological feature of the disease [2, 15, 27, 28],
and have suggested that dysregulated neurotrophin traf-
ficking is one of the main factors influencing early neuro-
degeneration [11, 16]. Our finding that axon development
is affected is consistent with previous studies showing that
expression of CMT2b Rab7 mutants can inhibit neurite
outgrowth in PC12 and Neuro2A cells in culture [11, 18].
In contrast, recent studies of Drosophila sensory neurons
showed normal size and complexity of dendritic arbors
expressing human L129F Rab7 at larval stages [19], and
apparently normal development of photoreceptor neurons
[15], suggesting neuronal development was not affected in
those models. These contrasting results could be due to
differences in the dependency on subcellular signaling
processes between axons and dendrites, or between differ-
ent cell types. For example, it is possible that photorecep-
tors are less dependent on neurotrophin signaling, and
axons and dendrites likely exhibit differences in their
dependencies on neurotrophin signaling. Our vertebrate
sensory axon model may be a better representation of the
long sensory axons affected in human disease. Develop-
mental effects of CMT2b are perhaps not surprising, as
neurotrophin signaling plays multiple important roles in
axon growth and branching, as well as in neuronal sur-
vival [29–31]. Moreover, the ability to extend an axon
during development could affect the neuron’s ability to
receive trophic support. However, we did not see in-
creased RB cell death at 3 dpf, suggesting neurons are still
receiving required trophic support. Our results showing
that axons fail to maintain branches during development
may partly explain the unusually early onset of CMT2b
disease, although we do not know if these axon defects
directly participate in later axon degeneration.
The effects we see on vesicle dynamics support the
idea that disrupted endosomal transport is a component
of the disease mechanism. CMT2b Rab7 mutant effects
on transport have been reported in other studies, although
there are some differences in findings. An in vitro study of
DRG neurons showed that vesicles containing CMT2b
Rab7 mutants move faster in the anterograde but not
retrograde direction [11]. However, in Drosophila, the
L129F CMT2b Rab7 mutant did not influence average
vesicle speed, but did decrease time spent in the stationary
phase [19]. We examined all four CMT2b Rab7 mutants,
and found varying effects on vesicle dynamics among the
individual mutants. We also saw a significant decrease in
the number of stationary vesicles containing N161T Rab7
and V162M Rab7 mutants, but not in cells expressing the
other CMT2b mutants. In contrast to the Zhang et al.
2013 [11] study, we found that K157N Rab7, but not the
other CMT2b mutants, caused a decrease in vesicle speed.
A potential explanation for these differing results may be
methodological. We quantified the fastest run speed
during a specified time period, whereas Zhang et al. quan-
tified the average vesicle speed. However, there also are
substantial differences between in vitro and in vivo
(See figure on previous page.)
Fig. 3 Central axon guidance errors in sensory axons expressing CMT2b Rab7 mutants. a-c Confocal projections (lateral views, anterior to the left)
of embryos labeled with HNK-1 antibody (red) and individual RBs expressing GFP-Rab7 forms (green). Drawings at right highlight morphology of
one neuron in green. a Wildtype GFP-Rab7 expressing neuron with two central axons traveling in the dorsal longitudinal fascicle (DLF), and with
one peripheral axon branching in the skin. b, c RB neurons expressing GFP-Rab7 L129F show lack of outgrowth of ascending central axon (b) or
central axon guidance errors (c). Central axon leaving DLF indicated by an arrow in (c). d Quantification of percentage of neurons lacking a central
axon. Cont = wildtype Rab7: n = 30 cells in 15 embryos; Rab7 L129F: n = 22 cells in 20 embryos, *p = 0.03; Rab7 K157N: n = 12 cells in 8 embryos,
*p = 0.02; Rab7 N161T: n = 16 cells in 11 embryos, p = 0.3; Rab7 V162M: n = 14 cells in 12 embryos, p = 0.3; Fisher’s exact tests. e Quantification of
percentage of cells with central axon guidance errors. Cont = wildtype Rab7: n = 30 cells in 15 embryos; Rab7 L129F: n = 24 cells in 19 embryos,
*p = 0.03; Rab7 K157N: n = 13 cells in 9 embryos, p = 0.3; Rab7 N161T: n = 13 cells in 11 embryos, p = 0.09; Rab7 V162M: n = 14 cells in 12 embryos,
p = 0.3. Scale bar = 40 μm
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systems. Developing neurons in vivo are under the
influence of the normal repertoire of extracellular signals
and guidance cues, including neurotrophin signaling,
which undoubtedly affect intracellular processes such as
receptor trafficking. Overall, varied results also may be
due to the differences in structural changes in the Rab7
proteins induced by individual CMT2b mutations. The
L129F substitution does not map to the nucleotide bind-
ing pocket, but is predicted to disrupt the positioning of
amino acids adjacent to the binding pocket, thus disrupt-
ing GTP-GDP cycling. The K157N and N161T substitu-
tions are predicted to cause a regional loss of secondary
Fig. 4 Decreased peripheral axon branching in transgenics expressing CMT2b Rab7 mutants. a-c Lateral views (anterior to the left) of RB neurons
labeled with HNK-1 antibody (brown) in 23 hpf transgenic embryos expressing wildtype GFP-Rab7 (a) or GFP-Rab7 L129F (b-c) in all RB neurons,
showing decreased branching in Tg(GFP-Rab7L129F) embryos. d-f Mosaic labeling of single RB cells with TagRFP-caax membrane label (red) in
23 hpf transgenic embryos expressing wildtype GFP-Rab7 (d) or GFP-Rab7 L129F (e, f) in all RB neurons. d Red-labeled RB in wildtype GFP-Rab7
transgenic embryo with widely branched peripheral axon. e Red-labeled RB in GFP-Rab7 L129F transgenic embryo does not extend a peripheral
axon. c Red-labeled RB in GFP-Rab7 L129F transgenic embryo extends a short peripheral axon that does not branch. Scale bar = 20 μm.
g Quantification of peripheral branches crossing horizontal myoseptum in 23 hpf Tg(-3.1ngn:gfp-Rab7) control (Cont) embryos (n = 14
embryos), Tg(-3.1ngn:gfp-Rab7 L129F) embryos (L129F, n = 63 embryos), and Tg(-3.1ngn:gfp-Rab7 K157N) embryos (K157N, n = 20 embryos).
****p < 0.0001, ***p = 0.0001. Unpaired, two-tailed t-test. h Number of peripheral branch tip endings in 23 hpf Tg(-3.1ngn:gfp-Rab7) control
(n = 9 cells in 6 embryos), Tg(-3.1ngn:gfp-Rab7 L129F) (n = 24 cells in 24 embryos), or Tg(-3.1ngn:gfp-Rab7 K157N) (n = 21 cells in 15 embryos) embryos
is significantly reduced in embryos expressing CMT2b-associated Rab7 mutants. **p = 0.002, *p = 0.04. Unpaired, two-tailed t-test. i-k Lateral views of
21 hpf embryos injected with ngn:TagRFP-caax and labeled with anti-TagRFP antibody. I, Example of RB with central axons only and no peripheral axon.
j Example of RB with a peripheral growth cone (g.c.) just initiating (arrow). Cell body (c.b.) is out of focus. k, Example of RB with short peripheral (with
2 endings, arrowheads) extended out of the spinal cord. Cell body (c.b.) is out of focus. l-m Quantification of percentage neurons with peripheral axons
at 18–19 hpf (l) and 20–21 hpf (m). There are no significant differences between wildtype and CMT2b Rab7 mutants. At 18–19 hpf: wildtype n = 65
neurons, CMT2b L129F n = 61 neurons, CMT2b K157N n = 10 neurons, p = 0.30 Chi-Square test. At 20–21 hpf: wildtype n = 75 neurons, CMT2b L129F
n = 28 neurons, CMT2b K157N n = 27 neurons, p = 0.15 Chi-Square test. n, Analysis of peripheral axon branch endings. At 18–19 hpf and 20–21 hpf,
wildtype vs. CMT2b K157N, *p = 0.03 unpaired student’s t-test
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structure around the binding pocket [12, 13]. Thus,
specific CMT2b Rab7 mutants may have variable effects
on the ability of vesicles to engage with motors and trans-
port along microtubules. Although differences exist in
details of study results, it is apparent that CMT2b Rab7
mutants affect endosomal trafficking, potentially in diverse
ways.
The question of whether the CMT2b-associated
mutations lead to overactive Rab7 versus loss of Rab7
function has been under debate. It appears likely that
a more complex alteration of function is involved. CMT2b
Rab7 mutants hydrolyze GTP slower than wildtype Rab7
[12, 13], which has led to the hypothesis that disease
effects are caused by overactive Rab7. Indeed several
previous studies are also consistent with this hypothesis,
as the effects they find can be mimicked with CA-Rab7
but not DN-Rab7 [11, 32–34]. The DN-Rab7 T22N
variant interferes with GTP binding, and has dominant
negative effects on endosomal trafficking [35]. However,
this construct does not have dominant effects in Drosoph-
ila neurons, suggesting it may not act as a dominant
negative under all conditions [15]. CMT2b mutants have
reduced binding to both GTP and GDP [12, 13], suggest-
ing these forms may have reduced Rab7 function. In
support of this idea, a recent Drosophila study showed
that CMT2b variants of Rab7 did not have dominant
effects and that loss of one rab7 allele caused defects in
photoreceptor synaptic function [15]. These authors con-
clude that CMT2b disease is in fact caused by reduced
Rab7 function. Our results showing decreased peripheral
axon branching in both CA-Rab7 and CMT2b Rab7
mutant expressing neurons are consistent with a model in
which overactivity of Rab7 contributes to these defects.
Interestingly, we found that some aspects of the pheno-
type caused by CMT2b Rab7 mutant expression in
our system, notably, the axon guidance defects, were
Fig. 5 Central axon guidance defects in transgenics expressing CMT2b Rab7 mutants. a Lateral (top two panels) and 3D rotation dorsal (bottom
two panels) views of TagRFP-caax labeled RB neuron in Tg(−3.1ngn:gfp-Rab7) embryo at 23 hpf showing ascending and descending ipsilateral
projections of central axons. Two bilateral rows of RB cells (green) are best seen in dorsal views. b-c Lateral (top two panels) and 3D rotation
dorsal (bottom two panels) views of TagRFP-caax labeled RB neurons in Tg(−3.1ngn:gfp-Rab7 L129F) embryos at 23 hpf. b Misguided descending
central axon (yellow arrow) turns around to travel anteriorly and dorsally from its normal pathway. c Misguided central axon (yellow arrowhead)
crosses dorsal midline to join the contralateral central fascicle. All views anterior to the left. Scale bar = 40 μm. d Quantification of number of
neurons with central axon guidance errors. Cont Rab7 = Tg(−3.1ngn:gfp-Rab7): 10 neurons in 7 embryos; Tg(−3.1ngn:gfp-Rab7 L129F): 43 cells in
43 embryos, *p = 0.05; Tg(−3.1ngn:gfp-Rab7K157M): 48 cells in 27 embryos, p = 0.2; Chi Square test
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not phenocopied by either CA-Rab7 or DN-Rab7. This
result, together with the diversity of findings from all
studies of CMT2b mutants, suggests the CMT2b Rab7
mutant proteins affect multiple cellular processes in dis-
tinct ways. The specific effects are likely highly context-
dependent, and may vary among cell types and processes
(e.g. axon growth or neuronal degeneration) depend-
ing on how reliant these processes are on particular
signals such as neurotrophin signaling. Continued study
of multiple in vivo models will be important for unraveling
the mechanisms of this complex disease.
Conclusions
In this study, we develop the first vertebrate model to
investigate the effects of CMT2b-associated alterations in
Rab7 protein on long projection sensory neurons, which
are the cells most profoundly affected in human disease.
We show previously unrecognized effects of CMT2b-
associated mutations on early axon development. These
results suggest axon developmental defects may be a
component of human CMT2b disease.
Methods
Animals
Adult zebrafish (Danio rerio) were kept in a 14/10 h light/
dark cycle. Embryos were maintained at 28.5 °C and
staged as hours post-fertilization (hpf) as described [36].
Wild type AB strain or transgenic Tg(−3.1ngn1:GFP-
Rab7), Tg(−3.1ngn1:GFP-Rab7L129F), Tg(−3.1ngn1:GFP-
Rab7K157N) embryos of either sex were used for all
experiments. All animal procedures were approved by
the Institutional Animal Care and Use Committee at
the University of Wisconsin (Animal Welfare Assurance
Number A3368-01).
Immunohistochemistry
Embryos were fixed overnight in 4 % paraformaldehyde
and labeled with monoclonal anti-HNK1 antibody (ZN-
12, 1:250; Zebrafish International Resource Center,
Eugene, OR), anti-HuC/D (1:500, Life Technologies), or
with mouse or rabbit anti-GFP antibody (1:1000; Invitro-
gen, Carlsbad, CA) and rabbit anti-TagRFP antibody
(1:500, Evitrogen). Antibody detection was performed with
a Vectastain IgG ABC detection kit (Vector Laboratories,
Burlingame, CA), or for fluorescent labeling, with Alexa-
Fluor488 and AlexaFluor568-conjugated secondary anti-
mouse or anti-rabbit antibodies (4 μg/mL; Invitrogen,
Carlsbad, CA).
Site-directed mutagenesis
The following primers were used to perform PCR-
mediated single-site mutagenesis to generate Rab7 L129F,










Fig. 6 CMT2b Rab7 mutants do not cause increased cell death at
3 dpf. a-b Lateral views of 3 dpf wildtype (a) and CMT2b L129F (b)
larvae labeled with anti-HuC/D in brown. Arrows indicate RB cell
bodies. c Quantification of cell body number in five segments
beginning at end of the yolk extension. CMT2b L129F is significantly
greater than wildtype, *p = 0.02, student’s t-test. N = 20 embryos for
each group
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Following PCR-directed mutagenesis, Rab7 constructs
were digested with Dpn1 (New England Biolabs) and
sequenced.
DNA constructs and injection
DNA expression constructs were made using Multisite
Gateway Cloning System (Invitrogen, Carlsbad, CA) into
Tol2 vectors [24]. Rab7, Rab7 T22N (DN) and Rab7 Q67L
(CA) constructs in Gateway pDONR vectors [22] were
obtained from Brian Link (Medical College of Wisconsin),
linked with N-terminal GFP, and cloned behind a cis-
regulatory element of the neurogenin1 gene (-3.1ngn1)
[20] to drive expression in RB neurons as described
previously [37]. To mosaically label RB cells, 11 pg of
-3.1ngn1:TagRFP-CAAX [37], or 25 pg -3.1ngn1:GFP-
Rab7, -3.1ngn1:GFP-Rab7L129F, -3.1ngn1:GFP-Rab7
K157N, -3.1ngn1:GFP-Rab7N161T, or -3.1ngn1:GFP-
V162M DNA was injected into one-cell stage embryos.
For transgenesis, AB wildtype embryos at the one-cell
stage were co-injected with 25 pg Tol2 transposase
mRNA along with 50 pg of either -3.1ngn1:GFP-Rab7,
-3.1ngn1:GFP-Rab7L129F or -3.1ngn1:GFP-Rab7K157N
DNA. Injected founder embryos were screened for fluores-
cence and GFP-positive progeny were raised to adulthood.
Brightfield and fluorescent fixed sample imaging
Brightfield images were captured on a Nikon (Tokyo,
Japan) TE300 inverted microscope with a Spot RT camera
(Diagnostic Instruments, Sterling Heights, MI). Fluores-
cent images of fixed embryos were captured with an
Olympus (Tokyo, Japan) FV1000 laser-scanning con-
focal microscope with a 40x (UPlan FLN air, NA 0.75)
objective.
Time lapse imaging
For live confocal imaging, embryos were anesthetized in
0.02 % tricaine and mounted in 1 % low melting agarose
Fig. 7 In vivo imaging of CMT2b Rab7 mutant containing vesicles reveals changes in endosome dynamics. a-b Confocal images of neurons with
GFP-Rab7 labeled endosomes in central (a) and peripheral (b) axons. b’ Kymograph of peripheral RB axon in red region in (b). Red lines indicate
rapid retrograde vesicle runs. c-d Confocal images of neurons with GFP-Rab7 N161T expressing endosomes in central (c) and peripheral (d) axons.
d’ Kymograph of peripheral axon in red region in (d). Red line indicates rapid retrograde vesicle runs. e Speeds of vesicles containing Rab7 K157
mutants were significantly reduced in central and peripheral axons. **p = 0.009, Unpaired, two-tailed t-test. Wildtype Rab7 control: n = 97 vesicles
in 8 cells in 6 embryos; Rab7 L129F: n = 37 vesicles in 6 cells in 4 embryos; Rab7 K157N: n = 24 vesicles in 3 cells in 2 embryos; Rab7 N161T n = 73
vesicles in 8 cells in 6 embryos; Rab7 V162M n = 33 vesicles in 5 cells in 3 embryos. f Decreased percentage of stationary vesicles in central and
peripheral axons expressing Rab7 N161T and V162M mutants. *p = 0.01, Fisher’s exact test. Wildtype Rab7 control: n = 39 vesicles in 8 cells in 6
embryos; Rab7 L129F: n = 86 vesicles in 6 cells in 4 embryos; Rab7 K157N: n = 37 vesicles in 3 cells in 2 embryos; Rab7 N161T n = 137 vesicles in
8 cells in 6 embryos; Rab7 V162M n = 60 vesicles in 5 cells in 3 embryos
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in 10 mM HEPES E3 medium as described [38]. Live high
speed imaging of endosomal trafficking was performed on
a Bruker Opterra swept field confocal microscope (Bruker
Nano Surfaces FM, Middleton, WI) equipped with a
Nikon CFI Plan Apo VC 60x oil immersion objective (NA
1.40). Embryos were 23 hpf at the beginning of the experi-
ment, and 1–20 1-μm optical sections were captured
every 2 s for a total duration of 400 s.
Quantification and data analysis
Fluorescent images and movies were processed and quan-
tified with Volocity Software (Perkin Elmer, Waltham,
MA). For axon growth/branching analysis, the only meas-
urement done in embryos that had all RB neurons labeled
with HNK-1 antibody was the counts of axon branches
crossing the horizontal myoseptum. Axon crosses over the
horizontal myoseptum were counted in somites 8–13 of
23 hpf embryos. All other axon measurements were done
on individually labeled neurons (accomplished by mosaic
expression of a fluorophore), a technique that allows the
entire neuron morphology to be clearly visualized without
obstruction from labeled neighboring axons. Neurons
were defined as lacking a peripheral axon when the cell
body and central axons were visible but no peripheral
axon was present. The number of peripheral axon endings
were also calculated from individually labeled neurons
when the entire arbor including tips of peripheral bran-
ches were visible. Axon tips were manually counted from
captured images or by examination through the micro-
scope. Axon guidance errors were defined as axons that
deviate from the stereotyped pathway and extend into
abnormal locations. For cell body number analysis, RB cell
bodies labeled with anti-HuC/D were manually counted
in a region spanning 5 somite segments, beginning at the
end of the yolk extension.
Endosomal trafficking movies were built in Volocity,
and corrected for drift in ImageJ [39]. Endosomal speeds
were measured in Volocity from kymographs made in
ImageJ. Speeds were measured during the fastest run per
vesicle in a 400 s imaging period. To determine endoso-
mal direction, we measured the net direction of each
individual punctum over 400 s, and categorized vesicle
movement as either anterograde (away from the cell
body), retrograde (toward the cell body), or no net
movement.
All statistical analyses were done using Prism 5.0
(GraphPad Software, Inc.). Errors are reported as standard
error of the mean (SEM).
Abbreviations
CA: constitutively active; CMT2b: Charcot-Marie-Tooth 2b; DN: dominant
negative; RB: Rohon-Beard.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
OYP conceived of the study, participated in study design, carried out the
experiments and data analysis, and co-wrote the manuscript. KWE developed
and provided imaging and analytical tools, and helped edit the manuscript.
MCH contributed to study conception, experimental design and data inter-
pretation, and co-wrote the manuscript. All authors read and approved the
manuscript.
Acknowledgements
This work was supported by National Institutes of Health Grants
R56NS086934, R01NS086934, and R01NS042228 to M.C.H., NRSA
F31NS074606 to O.Y.P., and R44MH065724 to K.W.E. We thank Julie Last for
assistance with swept field confocal microscopy, Jimmy Fong of Bruker
Technologies for swept field confocal technical assistance, Brian Link for Rab
constructs, Marc Wolman for HuC/D antibody, Aiden Sperry, Jacob Lee and
Jacob Miller for technical assistance. We are grateful to Kelsey Baubie, Kassie
Ford and Christina Lindop for fish care.
Author details
1Department of Zoology, University of Wisconsin, 1117 West Johnson St.,
Madison, WI 53706, USA. 2Department of Neuroscience, University of
Wisconsin, 1111 Highland Ave, Madison, WI 53705, USA. 3Neuroscience
Training Program, University of Wisconsin, 1111 Highland Ave, Madison, WI
53705, USA. 4Medical Scientist Training Program, University of Wisconsin, 750
Highland Ave, Madison, WI 53705, USA. 5Laboratory for Optical and
Computational Instrumentation, University of Wisconsin, 1675 Observatory
Dr, Madison, WI 53706, USA.
Received: 27 August 2015 Accepted: 11 January 2016
References
1. Barisic N, Claeys KG, Sirotkovic-Skerlev M, Lofgren A, Nelis E, De Jonghe P,
et al. Charcot-Marie-Tooth disease: a clinico-genetic confrontation. Ann
Hum Genet. 2008;72(Pt 3):416–41. doi:10.1111/j.1469-1809.2007.00412.x.
2. Rotthier A, Baets J, De Vriendt E, Jacobs A, Auer-Grumbach M, Levy N,
et al. Genes for hereditary sensory and autonomic neuropathies: a
genotype-phenotype correlation. Brain. 2009;132(Pt 10):2699–711.
doi:10.1093/brain/awp198.
3. Meggouh F, Bienfait HM, Weterman MA, de Visser M, Baas F. Charcot-Marie-
Tooth disease due to a de novo mutation of the RAB7 gene. Neurology.
2006;67(8):1476–8. doi:10.1212/01.wnl.0000240068.21499.f5.
4. Verhoeven K, De Jonghe P, Coen K, Verpoorten N, Auer-Grumbach M, Kwon
JM, et al. Mutations in the small GTP-ase late endosomal protein RAB7
cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet.
2003;72(3):722–7. doi:10.1086/367847.
5. Houlden H, King RH, Muddle JR, Warner TT, Reilly MM, Orrell RW, et al. A
novel RAB7 mutation associated with ulcero-mutilating neuropathy. Ann
Neurol. 2004;56(4):586–90. doi:10.1002/ana.20281.
6. Wang X, Han C, Liu W, Wang P, Zhang X. A Novel RAB7 Mutation in a
Chinese Family with Charcot-Marie-Tooth type 2B disease. Gene. 2013.
doi:10.1016/j.gene.2013.10.023.
7. Bucci C, Thomsen P, Nicoziani P, McCarthy J, van Deurs B. Rab7: a key to
lysosome biogenesis. Mol Biol Cell. 2000;11(2):467–80.
8. Hyttinen JM, Niittykoski M, Salminen A, Kaarniranta K. Maturation of
autophagosomes and endosomes: a key role for Rab7. Biochim Biophys
Acta. 2013;1833(3):503–10. doi:10.1016/j.bbamcr.2012.11.018.
9. Saxena S, Bucci C, Weis J, Kruttgen A. The small GTPase Rab7 controls
the endosomal trafficking and neuritogenic signaling of the nerve
growth factor receptor TrkA. J Neurosci. 2005;25(47):10930–40.
doi:10.1523/JNEUROSCI.2029-05.2005.
10. Deinhardt K, Salinas S, Verastegui C, Watson R, Worth D, Hanrahan S, et al. Rab5
and Rab7 control endocytic sorting along the axonal retrograde transport
pathway. Neuron. 2006;52(2):293–305. doi:10.1016/j.neuron.2006.08.018.
11. Zhang K, Fishel Ben Kenan R, Osakada Y, Xu W, Sinit RS, Chen L, et al. Defective
axonal transport of Rab7 GTPase results in dysregulated trophic signaling.
J Neurosci. 2013;33(17):7451–62. doi:10.1523/JNEUROSCI.4322-12.2013.
12. De Luca A, Progida C, Spinosa MR, Alifano P, Bucci C. Characterization of the
Rab7K157N mutant protein associated with Charcot-Marie-Tooth type 2B.
Biochem Biophys Res Commun. 2008;372(2):283–7. doi:10.1016/j.bbrc.2008.05.060.
Ponomareva et al. Neural Development  (2016) 11:2 Page 13 of 14
13. Spinosa MR, Progida C, De Luca A, Colucci AM, Alifano P, Bucci C.
Functional characterization of Rab7 mutant proteins associated with
Charcot-Marie-Tooth type 2B disease. J Neurosci. 2008;28(7):1640–8.
doi:10.1523/JNEUROSCI.3677-07.200828/7/1640.
14. McCray BA, Skordalakes E, Taylor JP. Disease mutations in Rab7 result in
unregulated nucleotide exchange and inappropriate activation. Hum Mol
Genet. 2010;19(6):1033–47. doi:10.1093/hmg/ddp567.
15. Cherry S, Jin EJ, Ozel MN, Lu Z, Agi E, Wang D, et al. Charcot-Marie-Tooth 2B
mutations in rab7 cause dosage-dependent neurodegeneration due to partial
loss of function. Elife. 2013;2:e01064. doi:10.7554/eLife.010642/0/e01064.
16. BasuRay S, Mukherjee S, Romero E, Wilson MC, Wandinger-Ness A. Rab7 mutants
associated with Charcot-Marie-Tooth disease exhibit enhanced NGF-stimulated
signaling. PLoS One. 2010;5(12):e15351. doi:10.1371/journal.pone.0015351.
17. Yamauchi J, Torii T, Kusakawa S, Sanbe A, Nakamura K, Takashima S, et al. The
mood stabilizer valproic acid improves defective neurite formation caused by
Charcot-Marie-Tooth disease-associated mutant Rab7 through the JNK
signaling pathway. J Neurosci Res. 2010;88(14):3189–97. doi:10.1002/jnr.22460.
18. Cogli L, Progida C, Lecci R, Bramato R, Kruttgen A, Bucci C. CMT2B-
associated Rab7 mutants inhibit neurite outgrowth. Acta Neuropathol.
2010;120(4):491–501. doi:10.1007/s00401-010-0696-8.
19. Janssens K, Goethals S, Atkinson D, Ermanoska B, Fransen E, Jordanova A,
et al. Human Rab7 mutation mimics features of Charcot-Marie-Tooth
neuropathy type 2B in Drosophila. Neurobiol Dis. 2014;65:211–9.
doi:10.1016/j.nbd.2014.01.021.
20. Blader P, Plessy C, Strahle U. Multiple regulatory elements with spatially and
temporally distinct activities control neurogenin1 expression in primary
neurons of the zebrafish embryo. Mech Dev. 2003;120(2):211–8.
21. Ponomareva OY, Holmen IC, Sperry AJ, Eliceiri KW, Halloran MC.
Calsyntenin-1 regulates axon branching and endosomal trafficking during
sensory neuron development in vivo. J Neurosci. 2014;34(28):9235–48.
doi:10.1523/JNEUROSCI.0561-14.201434/28/9235.
22. Clark BS, Winter M, Cohen AR, Link BA. Generation of Rab-based transgenic
lines for in vivo studies of endosome biology in zebrafish. Dev Dyn.
2011;240(11):2452–65. doi:10.1002/dvdy.22758.
23. Kawakami K. Tol2: a versatile gene transfer vector in vertebrates. Genome
Biol. 2007;8 Suppl 1:S7. doi:10.1186/gb-2007-8-s1-s7.
24. Kwan KM, Fujimoto E, Grabher C, Mangum BD, Hardy ME, Campbell DS,
et al. The Tol2kit: a multisite gateway-based construction kit for Tol2
transposon transgenesis constructs. Dev Dyn. 2007;236(11):3088–99.
doi:10.1002/dvdy.21343.
25. Williams JA, Barrios A, Gatchalian C, Rubin L, Wilson SW, Holder N.
Programmed cell death in zebrafish rohon beard neurons is influenced by
TrkC1/NT-3 signaling. Dev Biol. 2000;226(2):220–30. doi:10.1006/dbio.2000.9860.
26. Castellano-Munoz M, Peng AW, Salles FT, Ricci AJ. Swept field laser confocal
microscopy for enhanced spatial and temporal resolution in live-cell imaging.
Microsc Microanal. 2012;18(4):753–60. doi:10.1017/S1431927612000542.
27. Gemignani F, Marbini A. Charcot-Marie-Tooth disease (CMT): distinctive
phenotypic and genotypic features in CMT type 2. J Neurol Sci.
2001;184(1):1–9.
28. Auer-Grumbach M, De Jonghe P, Wagner K, Verhoeven K, Hartung HP,
Timmerman V. Phenotype-genotype correlations in a CMT2B family with
refined 3q13-q22 locus. Neurology. 2000;55(10):1552–7.
29. Ascano M, Bodmer D, Kuruvilla R. Endocytic trafficking of neurotrophins in neural
development. Trends Cell Biol. 2012;22(5):266–73. doi:10.1016/j.tcb.2012.02.005.
30. Aguayo AJ, Clarke DB, Jelsma TN, Kittlerova P, Friedman HC, Bray GM. Effects
of neurotrophins on the survival and regrowth of injured retinal neurons.
Ciba Found Symp. 1996;196:135–44. discussion 44–8.
31. Gallo G, Letourneau PC. Regulation of growth cone actin filaments by
guidance cues. J Neurobiol. 2004;58(1):92–102. doi:10.1002/neu.10282.
32. Taub N, Teis D, Ebner HL, Hess MW, Huber LA. Late endosomal traffic of the
epidermal growth factor receptor ensures spatial and temporal fidelity of
mitogen-activated protein kinase signaling. Mol Biol Cell. 2007;18(12):4698–710.
doi:10.1091/mbc.E07-02-0098.
33. BasuRay S, Mukherjee S, Romero EG, Seaman MN, Wandinger-Ness A. Rab7
mutants associated with Charcot-Marie-Tooth disease cause delayed growth
factor receptor transport and altered endosomal and nuclear signaling.
J Biol Chem. 2013;288(2):1135–49. doi:10.1074/jbc.M112.417766.
34. Cogli L, Progida C, Thomas CL, Spencer-Dene B, Donno C, Schiavo G, et al.
Charcot-Marie-Tooth type 2B disease-causing RAB7A mutant proteins show
altered interaction with the neuronal intermediate filament peripherin. Acta
Neuropathol. 2013;125(2):257–72. doi:10.1007/s00401-012-1063-8.
35. Feng Y, Press B, Wandinger-Ness A. Rab 7: an important regulator of late
endocytic membrane traffic. J Cell Biol. 1995;131(6 Pt 1):1435–52.
36. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of
embryonic development of the zebrafish. Dev Dyn. 1995;203(3):253–310.
37. Andersen E, Asuri N, Halloran M. In vivo imaging of cell behaviors and
F-actin reveals LIM-HD transcription factor regulation of peripheral versus
central sensory axon development. Neural Dev. 2011;6:27.
38. Andersen E, Asuri N, Clay M, Halloran M. Live imaging of cell motility and
actin cytoskeleton of individual neurons and neural crest cells in zebrafish
embryos. J Vis Exp. 2010;36. http://www.jove.com/video/1726/live-imaging-
cell-motility-actinactincytoskeleton-individual-neurons.
doi:10.3791/1726.
39. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of
image analysis. Nat Methods. 2012;9(7):671–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ponomareva et al. Neural Development  (2016) 11:2 Page 14 of 14
